Valuation: Biocon Limited

Market Cap 598B 6.36B 5.71B 5.21B 4.76B 8.97B 9.25B 62.85B 25.06B 319B 23.88B 23.37B 1,007B P/E 2027 *
82.3x
P/E 2028 * 38.6x
Enterprise Value 702B 7.47B 6.7B 6.12B 5.59B 10.53B 10.86B 73.78B 29.42B 375B 28.03B 27.43B 1,182B EV / Sales 2027 *
3.67x
EV / Sales 2028 * 3.13x
Free-Float
51.72%
Yield 2027 *
0.13%
Yield 2028 * 0.21%
1 day+0.59%
1 week+4.39%
Current month+4.39%
1 month+2.01%
3 months-13.86%
6 months-3.92%
Current year-6.77%
1 week 336.95
Extreme 336.95
368.05
1 month 318.4
Extreme 318.4
368.05
Current year 318.4
Extreme 318.4
447.15
1 year 318.4
Extreme 318.4
447.15
3 years 222.55
Extreme 222.55
447.15
5 years 191.55
Extreme 191.55
447.15
10 years 134.07
Extreme 134.066666
487.75
Manager TitleAgeSince
Investor Relations Contact - -
Chief Executive Officer - 01/04/2026
Director of Finance/CFO 48 01/04/2026
Director TitleAgeSince
Director/Board Member 64 24/04/2014
Director/Board Member 71 01/01/2000
Chairman 73 29/11/1978
Change 5-day change 1-year change 3-year change Capi.($)
+0.59%+4.39%-3.46%+62.97% 6.32B
-4.83%+3.51%+55.00%+63.79% 66.7B
+0.02%+1.07%+11.72%+75.63% 56.88B
-1.34%+2.98%+25.08%+100.18% 56.53B
+5.09%+9.89%+27.19%+105.85% 46.49B
+2.62%+1.68%+29.16%+35.86% 44.8B
+8.24%+0.51%+215.16%+794.74% 41.59B
-1.86%+10.13%+28.14%+55.48% 35.35B
-2.97%-9.84%+90.91%+73.49% 33.29B
+5.19%+1.62%-39.69%+368.87% 25.1B
Average +1.08%+2.76%+43.92%+173.69% 41.3B
Weighted average by Cap. +0.65%+3.08%+49.08%+164.30%

Financials

2027 *2028 *
Net sales 191B 2.03B 1.82B 1.67B 1.52B 2.87B 2.96B 20.1B 8.01B 102B 7.64B 7.47B 322B 220B 2.34B 2.1B 1.92B 1.75B 3.3B 3.41B 23.16B 9.23B 118B 8.8B 8.61B 371B
Net income 7.36B 78.27M 70.2M 64.16M 58.57M 110M 114M 773M 308M 3.93B 294M 287M 12.39B 14.61B 155M 139M 127M 116M 219M 226M 1.54B 612M 7.8B 584M 571M 24.62B
Net Debt 104B 1.11B 992M 907M 828M 1.56B 1.61B 10.93B 4.36B 55.48B 4.15B 4.06B 175B 92.17B 981M 879M 804M 734M 1.38B 1.43B 9.69B 3.86B 49.18B 3.68B 3.6B 155B
Projected Income Statement - Annual - Biocon Limited
Logo Biocon Limited
Biocon Limited is an India-based biopharmaceutical company, engaged in the manufacture of biotechnology products and research services. The Company is in the business of manufacturing active pharmaceutical ingredients (APIs) and formulations, including biosimilar drugs for diabetics, oncology and autoimmune diseases. The Company’s segment includes Generics, Biosimilars, Novel Biologics and Research Services. It focuses on three key therapeutic areas - Oncology, Diabetes, and Immunology. Its APIs portfolio includes cardiovascular, anti-diabetics, immunosuppressants, and specialty molecules. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. Its APIs manufacturing facilities with capabilities in microbial fermentation, downstream process, including chromatographic purification, chemical synthesis, peptide synthesis and Highly Potent APIs (HPAPIs). It has over five facilities in Bangalore, Hyderabad and Visakhapatnam in India.
Employees
16,447
Date Price Change Volume
08/11/26 ₹367.25 +0.59% 482,922
06/11/26 ₹365.10 +0.86% 5,123,511
05/11/26 ₹362.00 +5.10% 6,787,308
04/11/26 ₹344.45 +0.42% 8,966,739
03/11/26 ₹343.00 -3.30% 3,443,215
Trader
Investor
Global
Quality
ESG MSCI
B
MarketScreener Ratings - Biocon Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
365.10INR
Average target price
436.21INR
Spread / Average Target
+19.48%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Biocon Limited
  1. Stock Market
  2. Stocks
  3. BIOCON Stock